Viewing nowCombinationPibapen Capsule (Pitavastatin Calcium, Fenofibrate)
Pitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Eden Pharma Co., Ltd.

MFDS item code 202501060 · Approved 2025.04.30 · Insurance code 628902490
Treatment of mixed dyslipidemia in adults at high risk of coronary heart disease
Pitavastatin 2 mg monotherapy effectively controls LDL cholesterol levels in adult patients at high risk of coronary artery disease. However, this regimen is used for patients with combined dyslipidemia that elevates triglyceride levels and maintains low HDL cholesterol levels. Therefore, this medication is particularly suitable for treatment focused on LDL cholesterol management and aids in preventing cardiovascular disease in high-risk patients. Overall, pitavastatin plays an important role in the treatment of dyslipidemia and improves the patient's cholesterol levels.
Creatine kinase (CK) levels should be measured before treatment with this medicine. The baseline value may be used as a reference for determining whether CK levels have increased during treatment with this medicine. Do not measure CK after strenuous exercise or when other potential factors that may cause CK elevation are present, as interpretation of CK levels may be difficult. If CK levels are significantly elevated to more than 5 times the upper limit of normal at baseline, repeat the measurement after 5~7 days to confirm the result. If CK levels remain significantly elevated to more than 5 times the upper limit of normal at baseline after 5~7 days, treatment with this medicine should not be initiated. Regular monitoring of CK levels every 3 months during the first 12 months after starting treatment with this medicine is recommended, followed by periodic monitoring. Patients starting treatment with this medicine or increasing their statin dose should be informed of the risk of myopathy, and should be advised to consult their physician immediately if they experience unexplained muscle pain, tenderness, weakness, or cramps while taking this medicine. In such cases, CK levels should also be measured, and this medicine should be discontinued if CK levels are markedly elevated (more than 5 times the upper limit of normal). Discontinuation should be determined regardless of CK levels, taking into account the severity of muscle symptoms and whether they cause daily discomfort. Re-administration of this medicine is not recommended in patients suspected of having an inherited muscle disorder. Transaminase (AST, ALT) levels should be monitored before treatment with this medicine, every 3 months during the first 12 months after starting treatment, and periodically thereafter. Patients with elevated transaminase levels should be monitored carefully, and this medicine should be discontinued if AST or SGOT, or ALT or SGPT levels increase to more than 3 times the upper limit of normal. Systematic assessment by measuring creatinine clearance every 3 months during the first 12 months after starting treatment with this medicine is recommended, followed by periodic monitoring. If the creatinine level exceeds 50% of the upper limit of normal, this medicine should be discontinued. Secondary causes of hyperlipidemia, such as uncontrolled type 2 diabetes, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, and alcoholism, should be adequately treated before starting this medicine. Patients should follow a standard cholesterol-lowering diet before starting treatment and continue it during treatment. As the recommended dose, take 1 capsule once daily immediately after a meal. Serum lipid levels (total cholesterol (TC), LDL-C, and triglycerides (TG)) should be monitored in response to treatment. Bioequivalence of this medicine has not been established compared with concomitant administration of the existing single-ingredient products; therefore, do not switch patients receiving pitavastatin and fenofibrate concomitantly to this medicine. Patients with renal impairment: Do not administer this medicine to patients with moderate to severe renal impairment whose estimated glomerular filtration rate is less than 60mL/min/1.73m2.
This medication is a lipid-lowering agent and contains two components: pitavastatin calcium and fenofibrate. When taking this medication, muscle-related symptoms such as muscle pain, weakness, or cramps may occur, so if these symptoms arise, it is essential to consult with a physician. Particularly, elderly patients over 65 years, women, individuals with poor kidney function, those with uncontrolled hypothyroidism, and people with a history of genetic muscle disease should exercise additional caution. Additionally, since this medication may affect liver function, regular liver function tests should be conducted, and if there are any issues with the liver or elevated liver enzyme levels, the medication may need to be discontinued. Patients with moderate to severe renal impairment should not take this medication, and caution is also needed for those with mild renal impairment. This medication may increase the risk of muscle damage when taken with other lipid-lowering agents or certain medications, so if you are taking other medicines, you should inform your doctor or pharmacist. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age. During the course of taking this medication, regular monitoring of blood lipid levels, liver function, and kidney function is necessary to confirm treatment efficacy and identify adverse reactions. If overdosed, there is no specific antidote, so you should immediately visit a medical institution for treatment according to the symptoms. Finally, this medication should be kept out of reach of children and stored in its original container.
nasopharyngitis, upper respiratory infection, increased ALT, increased AST, increased GGT, abnormal liver function test, gastroesophageal reflux disease, nausea, headache, dizziness, increased CPK, hypertension, chronic gastritis, erosive gastritis, decreased hemoglobin, decreased white blood cell count, decreased platelet count, decreased granulocytes, decreased leukocytes, increased eosinophils, increased leukocytes, increased globulins, positive Coombs test, anemia, hypersensitivity, headache, fatigue, dizziness, stiffness, drowsiness, insomnia, heaviness, paralysis, thromboembolism, interstitial lung disease, gastrointestinal symptoms (abdominal pain, nausea, vomiting, diarrhea, bloating), pancreatitis, thirst, dyspepsia, abdominal distension, constipation, stomatitis, loss of appetite, glossitis, nausea, gastric discomfort, increased transaminases, cholelithiasis, jaundice, complications of cholelithiasis, increased bilirubin, increased cholinesterase, increased AST, increased ALT, increased γ-GT, increased ALP, increased LDH, decreased aldosterone, increased aldosterone, increased adrenocorticotropic hormone, increased cortisol, decreased testosterone, severe skin reaction, skin hypersensitivity, rash, itching, urticaria, alopecia, photosensitivity, muscle disorders, myalgia, myositis, muscle cramps, weakness, renal failure, rhabdomyolysis, myopathy, increased myoglobin, increased CPK, fatigue, polyuria, increased BUN, increased serum creatinine, sexual dysfunction, increased serum homocysteine levels, increased hematuria, palpitations, fatigue, skin pain, burning sensation, arthralgia, edema, blurred vision, photophobia, hearing loss, urinary hematuria, increased uric acid levels, elevated serum potassium and phosphate levels, taste disturbance, colored urine, lethargy, positive antinuclear antibody, hair loss, hypersensitivity, angioedema, urticaria, erythema
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The appropriate storage temperature is between 1 and 30 degrees Celsius, and it is advisable to avoid extremely hot or cold environments.
A hard capsule with an upper light green and lower white color containing a white round film-coated tablet and white spherical micro granules.
30 capsules/bottle, 300 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Dongkook Pharmaceutical Co., Ltd.
CombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Ahn-Gook Pharmaceutical Co., Ltd.
CombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Pitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationPitavastatin Calcium 2mg · Fenofibrate Granules 241.51mg
Hard capsule · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.